Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Toxic factors are enriched in exosome-enriched fractions prepared from MS B-cell Sup by ultracentrifugation Toxic factors are enriched in exosome-enriched.

Published byῬαΧάβ Αλεξανδρίδης Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2 Toxic factors are enriched in exosome-enriched fractions prepared from MS B-cell Sup by ultracentrifugation Toxic factors are enriched in exosome-enriched."— Presentation transcript:

1 Figure 2 Toxic factors are enriched in exosome-enriched fractions prepared from MS B-cell Sup by ultracentrifugation Toxic factors are enriched in exosome-enriched fractions prepared from MS B-cell Sup by ultracentrifugation (A) B cells were cultured in serum-free X-VIVO 10 defined medium. Five MS Sup showed greater toxicity to OL than 5 NC Sup. These results were similar to those obtained previously from B cells cultured in medium containing bovine serum (Lisak et al. 2017). (B) Medium alone, 3 NC, and 4 MS Sup were centrifuged at 62,500g for 2 hours (see Methods); the pellets, enriched in extracellular vesicles, were suspended in DMEM, diluted 1:4 with OL medium, and tested for OL toxicity. The pellets from MS samples retained toxicity compared with the NC samples. The background value for NC UC and MS UC toxicity is the value for the toxicity of the medium UC fraction (16%); subtraction of that value gives a range of −5% to 16% for NC UC and a range of 29%–40% for MS UC. Values represent averages, n = 2 ± range; *p < by analysis of variance with the Tukey post-test. NC = normal control; OL = oligodendrocyte; UC = ultracentrifugation. Joyce A. Benjamins et al. Neurol Neuroimmunol Neuroinflamm 2019;6:e550 Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Download ppt "Figure 2 Toxic factors are enriched in exosome-enriched fractions prepared from MS B-cell Sup by ultracentrifugation Toxic factors are enriched in exosome-enriched."

Similar presentations

Figure 2 ERG amplitude reduction in the follow-up study

Figure 2 ERG amplitude reduction in the follow-up study
Figure 1 Box plot of the venous diameter in lesions

Figure 1 Box plot of the venous diameter in lesions
Figure 1 Regional changes in FA values

Figure 1 Regional changes in FA values
Figure 1 Stiff-person syndrome spectrum patient serum bound to membranes of live GlyRα1-transfected HEK293 cells Stiff-person syndrome spectrum patient.

Figure 1 Stiff-person syndrome spectrum patient serum bound to membranes of live GlyRα1-transfected HEK293 cells Stiff-person syndrome spectrum patient.
Figure 2 Spinal cord lesions

Figure 2 Spinal cord lesions
Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.

Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.
Figure 4 Correlation of age with [11C](R)-PK11195 binding in the normal-appearing white matter (NAWM) and thalami Correlation of age with [11C](R)-PK11195.

Figure 4 Correlation of age with [11C](R)-PK11195 binding in the normal-appearing white matter (NAWM) and thalami Correlation of age with [11C](R)-PK11195.
Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production

Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 1 Comparison of miR-150-5p (log scale), prednisone dose (mg), and QMG score between the thymectomy (ETTX) and prednisone groups Comparison of miR-150-5p.

Figure 1 Comparison of miR-150-5p (log scale), prednisone dose (mg), and QMG score between the thymectomy (ETTX) and prednisone groups Comparison of miR-150-5p.
Figure 2 Neurochemical profiles for each neurocognitive trajectory

Figure 2 Neurochemical profiles for each neurocognitive trajectory
Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.

Figure Immune checkpoint inhibitor–induced encephalitis before and after treatment with natalizumab Immune checkpoint inhibitor–induced encephalitis before.
Figure 4 Detection of EBER+ cells in MS and control brains by in situ hybridization Detection of EBER+ cells in MS and control brains by in situ hybridization.

Figure 4 Detection of EBER+ cells in MS and control brains by in situ hybridization Detection of EBER+ cells in MS and control brains by in situ hybridization.
Figure 1 Linear relationship between CSF inflammation and glucose in meningitis; analysis stratified by diagnostic category (aseptic, n = 115 and microbial,

Figure 1 Linear relationship between CSF inflammation and glucose in meningitis; analysis stratified by diagnostic category (aseptic, n = 115 and microbial,
Figure 1 Quantitative spinal cord MRI maps and segmentations

Figure 1 Quantitative spinal cord MRI maps and segmentations
Figure 3 Gene expression in CSF cell pellets

Figure 3 Gene expression in CSF cell pellets
Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer

Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer
Figure Association of hippocampal subfield volumes to cognition by neopterin level, volumes, and cognition adjusted for age, education, race, sex, and.

Figure Association of hippocampal subfield volumes to cognition by neopterin level, volumes, and cognition adjusted for age, education, race, sex, and.
Figure 3 Temporal trends in FALS incidence

Figure 3 Temporal trends in FALS incidence
Table 4 Associations in SNP array data between the Braak stage and previously known AD risk loci (341 variants) comparing participants with Braak stage.

Table 4 Associations in SNP array data between the Braak stage and previously known AD risk loci (341 variants) comparing participants with Braak stage.

Similar presentations

Ads by Google